Sarepta Therapeutics's total assets for Q1 2026 were $3.18B, a decrease of -5.10% from the previous quarter. SRPT total liabilities were $1.67B for the fiscal quarter, a -24.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.